Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Ian Schofield
Pharma firms are being asked to let the government know how prepared they are in terms of ensuring supplies of investigational medicines and other clinical trial supplies in the event of a no-deal Brexit at the end of October.
Life science companies are uneasy over the government’s latest proposals for emergency medical supplies to the UK if the country leaves the EU without a deal.
The Italian authorities have agreed a new kind of reimbursement model for Novartis's CAR-T therapy Kymriah that involves payment in instalments depending on the patient’s response to treatment.
A review of barriers to the prescribing of cannabis-based medicines for children with epilepsy in England suggests that much needs to be done to generate the necessary evidence to assuage prescribers’ concerns.